Colinz Laboratories Ltd (COLINZ) — shareholding pattern, promoter holding, financials and share price
About Colinz Laboratories Ltd (COLINZ)
Colinz Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as COLINZ and on the BSE under scrip code 531210. Its ISIN is INE923C01011.
Incorporated in 1986, Colinz Laboratories is in the business of manufacturing and trading in pharmaceutical formulations [1]
Colinz Laboratories Limited is a pharmaceutical company established in 1986, focusing on manufacturing diverse dosage forms like tablets, capsules, and injectables.
The company operates a WHO-compliant plant in Sinnar, coupled with a comprehensive quality control laboratory, supporting its emphasis on quality production.
Listed peers in Pharmaceuticals: Beryl Drugs Ltd, Unjha Formulations Ltd, Vivanza Biosciences Ltd, Ganga Pharmaceuticals Ltd, Decipher Labs Ltd, Brawn Biotech Ltd.
Valuation & Returns
10 Jul 2026At ₹69.99 a share on 10 Jul 2026, Colinz Laboratories Ltd (COLINZ) was valued at a price-to-earnings ratio of 34.57x against an industry P/E of 36.41x and a price-to-book of 1.86x on a book value of ₹37.61 per share as of Mar 2025. Solomo computes return on equity of 5.38% and return on capital employed of 7.32% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 34.57x
- Industry P/E
- 36.41x
- P/B
- 1.86x
- EPS (TTM)
- ₹2.02
- Book value / share
- ₹37.61
- ROE
- 5.38%
- ROCE
- 7.32%
- ROA
- 4.32%
- Debt / equity
- 0.07x
- Dividend yield
- 0%
- EBITDA margin
- 14.66%
- 52-week range
- ₹36.11 – ₹87.91
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Colinz Laboratories Ltd (COLINZ) reported revenue of ₹6.14 crore, net profit of ₹0.51 crore and earnings per share of ₹2.02. That compares with revenue of ₹6.53 crore and net profit of ₹0.5 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1.75 crore and net profit ₹0.17 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 6.97 | 7.15 | 7.03 | 6.53 | 6.14 |
| Net profit (₹ cr) | 0.34 | 0.46 | 0.49 | 0.5 | 0.51 |
| EPS (₹) | 0.74 | 1.83 | 1.95 | 1.98 | 2.02 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -2.76% | -3.00% | -2.18% | -7.11% |
| Profit growth | 20.23% | 30.65% | 13.54% | 2.04% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 50.6% of Colinz Laboratories Ltd (COLINZ) (down 15.4 pp QoQ). Market capitalisation was ₹18 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: PADAM DUGAR 12.54%, ANNJANA DUGAR 1.59%, DIPAKBHAI HARIBHAI GAUDANI 1.31%, RASILABEN DIPAKBHAI GAUDANI 1.25%, HUF 1.05%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 50.6% | - | - | - | 49.4% |
| Mar 2026 | 66% | - | - | - | 34% |
| Dec 2025 | 66% | - | - | - | 34% |
| Sep 2025 | 66% | - | - | - | 34% |
| Jun 2025 | 66% | - | - | - | 34% |
| Mar 2025 | 66% | - | - | - | 34% |
| Dec 2024 | 66% | - | - | - | 34% |
| Sep 2024 | 66% | - | - | - | 34% |